NAD+

Oxidized β-nicotinamide adenine dinucleotide · non-peptide biochemical research coenzyme

Lot-specific multi-attribute release; verify identity, chromatographic purity, quantitative assay, supplied form, water and degradants on the batch COA · target, verify batch COACAS 53-84-9RUO

Research statusExtensively studied endogenous coenzyme; this material is Research Use Only

Supplied formNon-peptide small-molecule dinucleotide cofactor

Lead timeConfirmed with quote

NAD+ — White to off-white powder or lyophilized cake; confirm the supplied form and lot appearance on the batch COA

NAD+ — White to off-white powder or lyophilized cake; confirm the supplied form and lot appearance on the batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research relevance includes redox biochemistry, enzyme assays, metabolomics and analytical-reference work
Mechanistic importance does not demonstrate that an NAD+ product produces anti-aging, energy, cognitive, exercise or disease-treatment benefits in people.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 53-84-9
Formula: C₂₁H₂₇N₇O₁₄P₂
Molecular weight: 663.4 g/mol
Appearance: White to off-white powder or lyophilized cake; confirm the supplied form and lot appearance on the batch COA
Purity: Lot-specific multi-attribute release; verify identity, chromatographic purity, quantitative assay, supplied form, water and degradants on the batch COA · target, verify batch COA
Storage: Follow the released-lot COA and manufacturer stability instructions. Protect from moisture, heat and light. Powder shelf life and prepared-solution stability are different attributes; do not assign a solution hold time without lot- and matrix-specific stability data.
MOQ: On request
Lead time: Confirmed with quote

PubChem CID 925

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about NAD+

Oxidized beta-NAD is an endogenous dinucleotide coenzyme central to cellular redox reactions and a substrate for NAD+-consuming enzymes such as PARPs and sirtuins. Direct administered-NAD+ human evidence is limited and must be separated from studies of the precursors NR and NMN. This lot is a biochemical Research Use Only reagent, not an approved anti-aging, metabolic or neurological therapy.

Laboratory redox and enzyme assays, NAD+/NADH metabolomics, analytical method development and other qualified biochemical research
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

NAD+ accepts hydride equivalents in oxidoreductase reactions and cycles with NADH across glycolysis, the TCA cycle and mitochondrial electron transfer. It is also consumed by PARPs, sirtuins and other NAD+-dependent enzymes. Assay interpretation must distinguish NAD+, NADH and related metabolites and account for extraction, matrix and degradation controls.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context

Research areaMitochondrial research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Follow the SDS and institutional laboratory controls
FDA has warned that food-grade NAD+ is unsuitable for sterile compounding without appropriate processing and has described adverse events consistent with endotoxin exposure
Chemical purity does not establish sterility, low endotoxin or injectable suitability.

Interactions reported in the literature

Not applicable as patient advice
Experimental compatibility depends on assay design, pH, ionic strength, enzymes, substrates and matrix; validate it within the research protocol.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

NAD+ factory batch COAs

NAD+ 100 mg Factory batch COA protected preview

NAD+100 mg · WHJLP-NAD100-260701-A

NAD+ 500 mg Factory batch COA protected preview

NAD+500 mg · WHJLP-NAD500-260701-A

NAD+ 1000 mg Factory batch COA protected preview

NAD+1000 mg · WHJLP-NAD1000-260701-A

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require released-lot identity, chromatographic purity, assay/content, form or salt assignment, water, residual solvents and relevant degradation-product data
Define endotoxin, bioburden or sterility separately when the research application requires them
Appearance alone cannot establish identity or suitability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

NADP-0100MG100 mg10 vials

NADP-0500MG500 mg10 vials

NADP-1000MG1000 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA and manufacturer stability instructions. Protect from moisture, heat and light. Powder shelf life and prepared-solution stability are different attributes; do not assign a solution hold time without lot- and matrix-specific stability data.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 925, C₂₁H₂₇N₇O₁₄P₂, 663.4 g/mol and CAS 53-84-9 for the beta-NAD free-acid reference structure. Mechanistic and precursor context: the listed peer-reviewed reviews and trials. Direct administered-NAD+ context is limited. FDA's sterile-compounding reminder and January 2026 GenoGenix warning letter show why chemical purity cannot substitute for endotoxin, sterility and regulatory qualification.

01
Hallmarks of aging: An expanding universe
Cell · 2023 · peer-reviewed review (landmark/highly cited)
Open source
02
NAD+ and sirtuins in aging and disease
Trends in Cell Biology · 2014 · peer-reviewed review (foundational/landmark)
Open source
03
SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism
Genome Integrity · 2013 · peer-reviewed review
Open source
04
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Nature Communications · 2016 · peer-reviewed original research (first-in-human pharmacokinetic trial)
Open source
05
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review
American Journal of Physiology-Endocrinology and Metabolism · 2024 · peer-reviewed systematic review
Open source
06
Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials
Cureus · 2024 · peer-reviewed systematic review (PRISMA)
Open source
07
What is really known about the effects of nicotinamide riboside supplementation in humans
Science Advances · 2023 · peer-reviewed critical review
Open source
08
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
Frontiers in Aging · 2026 · peer-reviewed original research (retrospective pilot study)
Open source

Product FAQ

Questions buyers ask about NAD+

Is NAD+ a peptide, and what should its analytical package contain?+

No. Oxidized beta-NAD is a dinucleotide coenzyme, not a peptide. Qualification should establish the exact free-acid, salt or hydrate form; orthogonal identity such as LC-MS and a spectroscopic method; chromatographic purity and relevant NADH or degradation-related species; quantitative assay; water and residual solvents. HPLC area purity alone does not establish content, sterility or suitability for a biological assay.

Are NAD+, NADH, NMN and NR interchangeable procurement names?+

No. NAD+ is the oxidized dinucleotide coenzyme, NADH is its reduced redox partner, and NMN and NR are distinct biosynthetic precursors. Their structures, registry identifiers, molecular weights, analytical methods, stability and evidence differ. Results from oral NR or NMN studies cannot be relabelled as direct NAD+ results, and a purchase specification must name the exact entity and supplied form.

NAD+

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about NAD+

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

NAD+ factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Hallmarks of aging: An expanding universe

NAD+ and sirtuins in aging and disease

SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

What is really known about the effects of nicotinamide riboside supplementation in humans

Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting

Questions buyers ask about NAD+

Compare adjacent molecules and documentation needs.

MOTS-c (Human)

SS-31

Amino-1MQ

Humanin